美国 · 通讯社与实时数据 · Business Wire
Sumitomo Pharma America to Present New Clinical Data on Enzomenib and Nuvisertib at the 2026 American Society of Hematology Annual Meeting
– SMPA to present first data from ongoing Phase 2 clinical trial of enzomenib in patients with relapsed or refractory acute leukemia, with KMT2A rearrangements, an aggressive…
在 Business Wire 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.businesswire.com)
